Emerging therapies in multiple myeloma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 3, 2015, Pages 315-321

  El Amm, Joelle ^a   Tabbara, Imad A ^b  

^a Medicine and Oncology   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

histone deacetylase inhibitors; immunomodulatory drugs; monoclonal antibodies; multiple myeloma; proteasome inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DARATUMUMAB; DEXAMETHASONE; DINACICLIB; ELOTUZUMAB; EVEROLIMUS; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; IXAZOMIB; LENALIDOMIDE; MELPHALAN; MONOCLONAL ANTIBODY; OPROZOMIB; PANOBINOSTAT; PERIFOSINE; POMALIDOMIDE; PREDNISONE; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SIGNAL TRANSDUCTION MODULATOR; SILTUXIMAB; TABALUMAB; TANESPIMYCIN; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VORINOSTAT; IMMUNOLOGIC FACTOR; OLIGOPEPTIDE; PHOSPHORYLCHOLINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CORTICOSTEROID THERAPY; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; REVIEW; SURVIVAL RATE; ANALOGS AND DERIVATIVES; DRUG EFFECTS; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; OLIGOPEPTIDES; PHOSPHORYLCHOLINE; PROTEASOME INHIBITORS; SIGNAL TRANSDUCTION; THALIDOMIDE;

EID: 84930761105     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182a4676b     Document Type: Review

References (77)

1. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood. 2009;114:5436-5443.
2. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521-2526.
3. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67:6383-6391.
4. Jain S, Diefenbach C, Zain J, et al. Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evid. 2011;6:43-57.
5. Moreau P, Richardson P, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120:947-959.
6. O'Connor OA, Stewart AK, Vallone M, et al. A phase I dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009;15:7085-7091.
7. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817-2825.
8. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012;119:5661-5670.
9. Badros AZ, Vig R, Martin T, et al. Carfilzomib in patients with multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013. Doi: 10.1038/Leu.2013.29 [Epub ahead of print].
10. 2 expansion cohort of PX-171-007. Blood. 2011;118. Abstract 2930.
11. Singhal S, Siegel D, Martin T, et al. Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): and updated analysis. Blood. 2011;118. Abstract 1876.
12. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120:1801-1809.
13. Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20: 1467-1473.
14. Sonneveld P, Asselbergs E, Zweegman S, et al. Carfilzomib combined with thalidomide and dexamethasone (CTD) is a highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (MM) who are transplant candidate. Blood. 2012;120. Abstract 333.
15. Mikhael JR, Reeder CB, Libby EN, et al. Results from the phase II dose expansion of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma. Blood. 2012;120. Abstract 445.
16. Palumbo A, Bringhen S, Villani O, et al. Carfilzomib, cyclo-phosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma (MM) patients. Blood. 2012;120. Abstract 730.
17. ClinicalTrials.gov. Phase 3 study comparing carfilzomib, lenalido-mide, and dexamethasone (CRd) versus lenalidomide and dexa-methasone (Rd) in subjects with relapsed multiple myeloma. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01080391. Accessed January 30, 2013.
18. ClinicalTrials.gov. A study of carfilzomib vs. best supportive care in subjects with relapsed and refractory multiple myeloma (FOCUS). Available at: http://clinicaltrials.gov/show/NCT01302392. Accessed January 30, 2013.
19. ClinicalTrials.gov. Phase 3 study with carfilzomib and dexame-thasone versus velcade and dexamethasone for relapsed multiple myeloma patients (ENDEAVOR). Available at: http://clinical trials.gov/ct2/show/NCT01568866. Accessed January 30, 2013.
20. Lentzsch S, LeBalne R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17:41-44.
21. Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD 34+ progenitor cells. Cancer Res. 2007;67: 746-755.
22. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380-386.
23. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory (IMiDS) in multiple myeloma. Leukemia. 2010;24:22-32.
24. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22: 3269-3276.
25. Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006;107:3098-3105.
26. Richardson P, Siegel D, Baz R, et al. A phase 1/2 multi-center, randomized, open label escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. Blood. 2009;114. Abstract 301.
27. Streetly MJ, Gyertson K, Daniel Y, et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141:41-51.
28. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27:5008-5014.
29. Michael J, Gertz M, Hayman S, et al. Long-term efficacy and duration of response of pomalidomide in patients with relapsed multiple myeloma. Haematologica. 2011;suppl 1:P-300.
30. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24:1934-1939.
31. Richardson PG, Siegel D, Vij R, et al. Randomized, open label phase study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib: phase 2 results. Blood. 2011;118. Abstract 634.
32. Jagannath S, Hofmeister CC, Siegel DS, et al. Pomalidomide (POM) with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior therapy with lenalidomide (LEN) and bortezomib (BORT): updated phase 2 results and age subgroup analysis. Blood. 2012;120. Abstract 450.
33. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease. Blood. 2011;118:2970-2975.
34. Lacy MQ, Kumar SK, LaPlant BR, et al. Pomalidomide plus low-dose dexamethasone (Pom/Dex) in relapsed myeloma: long term follow up and factors predicting outcome in 345 patients. Blood. 2012;120. Abstract 201.
35. Leleu X, Attal M, Arnulf B, et al. High response rates to pomalidomide and dexamethasone in patients with refractory myeloma, final analysis of IFM 2009-02. Blood. 2011;118. Abstract 812.
36. Leleu X, Roussel M, Arnulf B, et al. Prolonged overall survival with pomalidomide and dexamethasone in myeloma characterized with end stage disease. Blood. 2012;120. Abstract 2961.
37. Shah JJ, Stadtmauer EA, Abonour R, et al. A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. Blood. 2012;120. Abstract 74.
38. Mark TM, Boyer A, Rossi AC, et al. ClaPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma. Blood. 2012;120. Abstract 77.
39. Palumbo A, Larocca A, Montefusco V, et al. Pomalidomide cyclophosphamide and prednisone (PCP) treatment for relapsed/refractory multiple myeloma. Blood. 2012;120. Abstract 446.
40. Dimopoulos MA, Lacy MQ, Moreau P, et al. Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: a phase 3, multicenter, randomized, open-label study. Blood. 2012;120:LBA-6.
41. Anderson KC. The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012;30:445-452.
42. Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment for multiple myeloma. Clin Cancer Res. 2008;14:2775-2784.
43. Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329-1337.
44. Boles KS, Stepp SE, Bennett M, et al. 2B4 (CD244) and CS1: novel members of the CD2subset of the immunoglobulin super-family molecules expressed on natural killer cells and other leukocytes. Immunol Rev. 2001;181:234-249.
45. Garg TK, Szmania S, Shi J, et al. Ex vivo activated natural killer (NK) cells from myeloma patients kill autologous myeloma and killing is enhanced by elotuzumab. Blood. 2008;112. Abstract 3666.
46. Van Rhee F, Szmania SM, Dillon M, et al. Combinational efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009; 8:2616-2624.
47. Rice AG, Dillon MB, Van Abberma AM, et al. HuLuc63 in combination regimens with conventional and targeted therapies has additive and synergistic anti-tumor activity in pre-clinical models of myeloma. Blood. 2007;110. Abstract 2517.
48. Lonial S, Vij R, Harousseau J-L, et al. Elotuzumab in combination with lenalidomide and lowdose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30:1953-1960.
49. Moreau P, Gerard P, Richardson G, et al. A randomized phase II study of elotuzumab with lenalidomide and low-dose dexametha-sone in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2012;30(suppl):8020, Meeting abstracts.
50. Richardson PG, Jagannath S, Moreau P, et al. A Phase 2 study of elotuzumab (Elo) in combination with lenalidomide and low-dose dexamethasone (Ld) in Patients with relapsed/refractory multiple myeloma (R/R MM): updated Results. Blood. 2012;120. Abstract 202.
51. Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2011;30:1960-1965.
52. Clinicaltrials.gov, Phase III study of lenalidomide and dexametha-sone with or without elotuzumab to treat relapsed or refractory multiple myeloma (ELOQUENT-2) NCT01239797. Available at: http://clinicaltrials.gov/ct2/show/NCT01239797?term=NCT01239797 &rank=1. Accessed January 30, 2013.
53. Hideshima T, Catley I, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107:4053-4062.
54. David E, Sinha R, Chen J, et al. Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regu-lation of death receptors. Clin Cancer Res. 2008;14:5090-5098.
55. Hideshima T, Catley L, Raje N, et al. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007;138:783-791.
56. Richardson PG, Wolf J, Jakubowiak A, et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011;29:4243-4249.
57. Clinicaltrials.gov, Assessment of efficacy and safety of perifosine, bortezomib and dexamethasone in multiple myeloma patients. NCT01002248. Available at: http://clinicaltrials.gov/ct2/results? term=NCT01002248&Search=Search. Accessed January 30, 2013.
58. Richardson PG, Mitsiades CS, Colson K, et al. Final results of a phase I trial of oral vorinostat in patients with advanced multiple myeloma. Blood. 2007;110. Abstract 1179.
59. Niesvizky R, Ely S, Mark T, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011;117:336-342.
60. Wolf JL, Siegel D, Goldschmidt H, et al. A phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012;53:1820-1823.
61. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): success and challenges. Cancer Lett. 2009;280:233-241.
62. Berenson JR, Yellin O, Boccio RV, et al. A phase I study of oral melphalan combined with LBH589 for patients with relapsed or refractory multiple myeloma (MM). Blood. 2009;114. Abstract 1855.
63. San-Miguel JF, Sezer O, Siegel DS, et al. A phase IB, multicenter, open-label dose escalation study of oral panobinostat (LBH589) and I.V bortezomib in patients with relapsed multiple myeloma. Blood. 2009;114. Abstract 3852.
64. Richardson PG, Alsina M, Weber D, et al. Panobinostat combined with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma. Blood. 2012;120. Abstract 1852.
65. Richardson PG, Alsina M, Weber DM, et al. Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib an dexamethasone in relapsed and bortezomib-refractory multiple myeloma (PANORAMA-2). Blood. 2011;118. Abstract 814.
66. San-Miguel JF, Moreau P, Yoon S-S, et al. Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1). J Clin Oncol. 2012;30(suppl):e18572, Meeting abstracts.
67. Siegel DS, Dimopoulos MA, Yoon S-S, et al. Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. Blood. 2011;114. Abstract 480.
68. Dimopoulos MA, Jagannath S, Yoon SS, et al. Vantage 088:vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial. Blood. 2011;118. Abstract 811.
69. Voorhees PM, Manges RF, Sonneveld P, et al. A phase 2 multicenter study of siltuximab, an anti-IL6 monoclonal antibody in patients with relapsed or refractory multiple myeloma. Blood. 2011;118. Abstract 3971.
70. Jagannath S, Chanan-Khan AA, Heffner LT, et al. BT 062, an antibody-drug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed/refractory multiple myeloma. Blood. 2011;118. Abstract 305.
71. Plesner T, Lokhorst H, Gimsing P, et al. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma-data from a dose-escalation phase I/II study. Blood. 2012;120. Abstract 73.
72. Kumar SK, LaPlant BR, Chng WJ, et al. Phase 1/2 trial of a novel CDK inhibitor dinaciclib (SCH727965) in patients with relapsed multiple myeloma demonstrates encouraging single agent activity. Blood. 2012;120. Abstract 76.
73. Raje N, Faber EA, Richardson PG, et al. Phase 1 study of tabalumab, a human anti-BAFF antibody and bortezomib in patients with previously-treated multiple myeloma. Blood. 2012;120. Abstract 447.
74. Kumar S, Bensinger WI, Reeder CB, et al. Weekly dosing of the investigational oral proteasome inhibitor MLN 9708 in patients with relapsed and/or refractory multiple myeloma: results from a phase I dose-escalation study. Blood. 2011;118. Abstract 816.
75. Kumar SK, Berdeja JG, Niesvizky R, et al. A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). Blood. 2012;120. Abstract 332.
76. Richardson PG, Spencer A, Cannell P, et al. Phase I clinical evaluation of twice-weekly marizomib, a novel proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma. Blood. 2011;118. Abstract 302.
77. Savona M, Berdeja JG, Lee SJ, et al. A phase 1b dose-escalation study of split-dose oprozomib in patients with hematologic malignancies. Blood. 2012;120. Abstract 203.